Key findings include: 1) The A allele of rs9939609 and G allele of rs17817449 were significantly enriched in MetS patients; 2) Both variants demonstrated allele dose-dependent worsening of MetS components; and 3) Dyslipidemia and hyperglycemia work as the primary pathways linking FTO variants to MetS susceptibility. This evidence concerns the gene FTO and Hyperglycemia.